KR20200036914A - 디히드로옥사디아지논 - Google Patents
디히드로옥사디아지논 Download PDFInfo
- Publication number
- KR20200036914A KR20200036914A KR1020207005998A KR20207005998A KR20200036914A KR 20200036914 A KR20200036914 A KR 20200036914A KR 1020207005998 A KR1020207005998 A KR 1020207005998A KR 20207005998 A KR20207005998 A KR 20207005998A KR 20200036914 A KR20200036914 A KR 20200036914A
- Authority
- KR
- South Korea
- Prior art keywords
- group
- dihydro
- trifluoromethyl
- phenyl
- oxadiazin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 *CC1OC1c1cc(*)c(*)c(*)c1 Chemical compound *CC1OC1c1cc(*)c(*)c(*)c1 0.000 description 14
- FZESPVBONPPRAW-UHFFFAOYSA-N Cc1nc(nccc2)c2[nH]1 Chemical compound Cc1nc(nccc2)c2[nH]1 FZESPVBONPPRAW-UHFFFAOYSA-N 0.000 description 2
- KNMKLBIEFWXRMO-UHFFFAOYSA-N CC(C(c(cc1)ccc1Br)=NN1)OC1=O Chemical compound CC(C(c(cc1)ccc1Br)=NN1)OC1=O KNMKLBIEFWXRMO-UHFFFAOYSA-N 0.000 description 1
- AEHBLEUGQTXZCM-UHFFFAOYSA-N CC(C)(C1)C1/N=C\Nc(cc1)c(C(F)(F)F)cc1C(CO1)=NNC1=O Chemical compound CC(C)(C1)C1/N=C\Nc(cc1)c(C(F)(F)F)cc1C(CO1)=NNC1=O AEHBLEUGQTXZCM-UHFFFAOYSA-N 0.000 description 1
- IJIXSFTWANOINL-UHFFFAOYSA-N CC(c(cc1F)cc(C(F)(F)F)c1Cl)=O Chemical compound CC(c(cc1F)cc(C(F)(F)F)c1Cl)=O IJIXSFTWANOINL-UHFFFAOYSA-N 0.000 description 1
- CAHDPRAPCFFDOO-UHFFFAOYSA-N CCCNc(cc1)c(C(F)(F)F)cc1C(CO1)=NNC1=O Chemical compound CCCNc(cc1)c(C(F)(F)F)cc1C(CO1)=NNC1=O CAHDPRAPCFFDOO-UHFFFAOYSA-N 0.000 description 1
- LMSLRBRLMMNGRO-UHFFFAOYSA-N CN(C(c(cc1)cc(C(F)(F)F)c1Cl)=O)OC Chemical compound CN(C(c(cc1)cc(C(F)(F)F)c1Cl)=O)OC LMSLRBRLMMNGRO-UHFFFAOYSA-N 0.000 description 1
- KEONFINAMASGKS-UHFFFAOYSA-N CN(C)CCNc(cc1)c(C(F)(F)F)cc1C(CO1)=NNC1=O Chemical compound CN(C)CCNc(cc1)c(C(F)(F)F)cc1C(CO1)=NNC1=O KEONFINAMASGKS-UHFFFAOYSA-N 0.000 description 1
- SLFLVMDVUVUVSU-RDDDGLTNSA-N C[C@H]([C@@H](CO)Nc(cc1)c(C(F)(F)F)cc1C(CO1)=NN[IH]1=O)O Chemical compound C[C@H]([C@@H](CO)Nc(cc1)c(C(F)(F)F)cc1C(CO1)=NN[IH]1=O)O SLFLVMDVUVUVSU-RDDDGLTNSA-N 0.000 description 1
- DHFMKSFJSZQVFE-UHFFFAOYSA-N C[n]1c(CNc(cc2)c(C(F)(F)F)cc2C(CO2)=NNC2=O)ncc1 Chemical compound C[n]1c(CNc(cc2)c(C(F)(F)F)cc2C(CO2)=NNC2=O)ncc1 DHFMKSFJSZQVFE-UHFFFAOYSA-N 0.000 description 1
- IBJVKSNORDBFND-UHFFFAOYSA-N Cc([nH]nc1C)c1-c(c(C(F)(F)F)c1)ccc1C(CO1)=NNC1=O Chemical compound Cc([nH]nc1C)c1-c(c(C(F)(F)F)c1)ccc1C(CO1)=NNC1=O IBJVKSNORDBFND-UHFFFAOYSA-N 0.000 description 1
- LWMHRSVMMMBCSM-UHFFFAOYSA-N Cc(cc(cc1)C(CO2)=NNC2=O)c1-c1cnc(C)nc1 Chemical compound Cc(cc(cc1)C(CO2)=NNC2=O)c1-c1cnc(C)nc1 LWMHRSVMMMBCSM-UHFFFAOYSA-N 0.000 description 1
- YLUKCTBUOSXKSW-UHFFFAOYSA-N Cc1c(-c(cc2)ccc2F)ccc(C(CO2)=NNC2=O)c1 Chemical compound Cc1c(-c(cc2)ccc2F)ccc(C(CO2)=NNC2=O)c1 YLUKCTBUOSXKSW-UHFFFAOYSA-N 0.000 description 1
- QXGXIMVUONSLBZ-UHFFFAOYSA-N Cc1cc(C(CO2)=NNC2=O)ccc1-c1cccnc1 Chemical compound Cc1cc(C(CO2)=NNC2=O)ccc1-c1cccnc1 QXGXIMVUONSLBZ-UHFFFAOYSA-N 0.000 description 1
- HKMIWVOZJIODIY-UHFFFAOYSA-N N#Cc1cc(C(CO2)=NNC2=O)cc(Cl)c1N1CCOCC1 Chemical compound N#Cc1cc(C(CO2)=NNC2=O)cc(Cl)c1N1CCOCC1 HKMIWVOZJIODIY-UHFFFAOYSA-N 0.000 description 1
- MRAKZGZXMJKEHM-UHFFFAOYSA-N NCCNc(cc1)c(C(F)(F)F)cc1C(CO1)=NNC1=O Chemical compound NCCNc(cc1)c(C(F)(F)F)cc1C(CO1)=NNC1=O MRAKZGZXMJKEHM-UHFFFAOYSA-N 0.000 description 1
- APDMMPQGTUFMNL-UHFFFAOYSA-N Nc(nc1)ncc1-c(ccc(C(CO1)=NN[IH]1=O)c1)c1F Chemical compound Nc(nc1)ncc1-c(ccc(C(CO1)=NN[IH]1=O)c1)c1F APDMMPQGTUFMNL-UHFFFAOYSA-N 0.000 description 1
- BUNOSKWLVXNWEH-UHFFFAOYSA-N O=C(CBr)c(cc1)cc(C(F)(F)F)c1F Chemical compound O=C(CBr)c(cc1)cc(C(F)(F)F)c1F BUNOSKWLVXNWEH-UHFFFAOYSA-N 0.000 description 1
- IPFKZFUYGAMYLV-UHFFFAOYSA-N O=C1OCC(c(cc2)cc(C(F)(F)F)c2-c(c(F)c2F)ccc2F)=NN1 Chemical compound O=C1OCC(c(cc2)cc(C(F)(F)F)c2-c(c(F)c2F)ccc2F)=NN1 IPFKZFUYGAMYLV-UHFFFAOYSA-N 0.000 description 1
- YLAALOFZOYCMGZ-UHFFFAOYSA-N O=C1OCC(c(cc2)cc(C(F)(F)F)c2-c2ccc(cc[nH]3)c3c2)=NN1 Chemical compound O=C1OCC(c(cc2)cc(C(F)(F)F)c2-c2ccc(cc[nH]3)c3c2)=NN1 YLAALOFZOYCMGZ-UHFFFAOYSA-N 0.000 description 1
- LKPHAELTCVRPDD-UHFFFAOYSA-N O=C1OCC(c(cc2)cc(C(F)F)c2-c(cc2)ccc2Cl)=NN1 Chemical compound O=C1OCC(c(cc2)cc(C(F)F)c2-c(cc2)ccc2Cl)=NN1 LKPHAELTCVRPDD-UHFFFAOYSA-N 0.000 description 1
- YQNZHHDYPPXVSY-UHFFFAOYSA-N O=C1OCC(c(cc2)cc(C(F)F)c2C2=CCCC2)=NN1 Chemical compound O=C1OCC(c(cc2)cc(C(F)F)c2C2=CCCC2)=NN1 YQNZHHDYPPXVSY-UHFFFAOYSA-N 0.000 description 1
- JQDCNNPSPGGZTR-UHFFFAOYSA-N O=C1OCC(c(cc2)cc(F)c2-c(cc2F)ccc2F)=NN1 Chemical compound O=C1OCC(c(cc2)cc(F)c2-c(cc2F)ccc2F)=NN1 JQDCNNPSPGGZTR-UHFFFAOYSA-N 0.000 description 1
- ONOBXOKMJSCRHY-UHFFFAOYSA-N O=C1OCC(c(cc2C(F)(F)F)ccc2-c(cc(cc2)F)c2F)=NN1 Chemical compound O=C1OCC(c(cc2C(F)(F)F)ccc2-c(cc(cc2)F)c2F)=NN1 ONOBXOKMJSCRHY-UHFFFAOYSA-N 0.000 description 1
- PGBJPGOKOJDZBV-UHFFFAOYSA-N O=[IH]1OCC(c(cc2)cc(C(F)(F)F)c2NC2CCNCC2)=NN1 Chemical compound O=[IH]1OCC(c(cc2)cc(C(F)(F)F)c2NC2CCNCC2)=NN1 PGBJPGOKOJDZBV-UHFFFAOYSA-N 0.000 description 1
- ZYZSXZNSWHTZTD-UHFFFAOYSA-N O=[IH]1OCC(c(cc2)cc(C(F)(F)F)c2NCC2CCOCC2)=NN1 Chemical compound O=[IH]1OCC(c(cc2)cc(C(F)(F)F)c2NCC2CCOCC2)=NN1 ZYZSXZNSWHTZTD-UHFFFAOYSA-N 0.000 description 1
- RYEDLYIBTBQTOE-UHFFFAOYSA-N O=[IH]1OCC(c(cc2)cc(C(F)(F)F)c2NCc2cccnn2)=NN1 Chemical compound O=[IH]1OCC(c(cc2)cc(C(F)(F)F)c2NCc2cccnn2)=NN1 RYEDLYIBTBQTOE-UHFFFAOYSA-N 0.000 description 1
- QYEIFDMKGKWJNH-UHFFFAOYSA-N Oc1cc(-c(cc2)c(C(F)(F)F)cc2C(CO2)=NNC2=O)ccc1F Chemical compound Oc1cc(-c(cc2)c(C(F)(F)F)cc2C(CO2)=NNC2=O)ccc1F QYEIFDMKGKWJNH-UHFFFAOYSA-N 0.000 description 1
- JAQMNYDOINQFGV-UHFFFAOYSA-N Oc1cc(-c(ccc(C(CO2)=NNC2=O)c2)c2F)ccc1 Chemical compound Oc1cc(-c(ccc(C(CO2)=NNC2=O)c2)c2F)ccc1 JAQMNYDOINQFGV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
- C07D273/04—Six-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Catalysts (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762541627P | 2017-08-04 | 2017-08-04 | |
| US62/541,627 | 2017-08-04 | ||
| PCT/EP2018/071039 WO2019025562A1 (fr) | 2017-08-04 | 2018-08-02 | Dihydrooxadiazinones |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20200036914A true KR20200036914A (ko) | 2020-04-07 |
Family
ID=63207725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207005998A Withdrawn KR20200036914A (ko) | 2017-08-04 | 2018-08-02 | 디히드로옥사디아지논 |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US11427553B2 (fr) |
| EP (1) | EP3661517B1 (fr) |
| JP (2) | JP7676141B2 (fr) |
| KR (1) | KR20200036914A (fr) |
| CN (1) | CN111212647B (fr) |
| AR (1) | AR112402A1 (fr) |
| AU (1) | AU2018309356B2 (fr) |
| BR (1) | BR112020002351A2 (fr) |
| CA (1) | CA3071800A1 (fr) |
| CL (1) | CL2020000303A1 (fr) |
| CO (1) | CO2020001242A2 (fr) |
| CR (1) | CR20200057A (fr) |
| CU (1) | CU24608B1 (fr) |
| EA (1) | EA202090448A1 (fr) |
| EC (1) | ECSP20008441A (fr) |
| IL (1) | IL272098B2 (fr) |
| JO (1) | JOP20200024A1 (fr) |
| MA (1) | MA49750A (fr) |
| MX (1) | MX2020001404A (fr) |
| PE (1) | PE20200936A1 (fr) |
| PH (1) | PH12020500134A1 (fr) |
| SG (1) | SG11201913775UA (fr) |
| TW (1) | TWI791581B (fr) |
| UA (1) | UA125731C2 (fr) |
| UY (1) | UY37832A (fr) |
| WO (1) | WO2019025562A1 (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20200024A1 (ar) | 2017-08-04 | 2020-02-02 | Bayer Ag | مركبات ثنائي هيدروكساديازينون |
| CA3071795A1 (fr) | 2017-08-04 | 2019-02-07 | Bayer Aktiengesellschaft | Derives de 6-phenyl-4,5-dihydropyridazin-3(2h)-one utilises en tant qu'inhibiteurs de pde3a et pde3b pour le traitement du cancer |
| TW202031677A (zh) | 2018-11-01 | 2020-09-01 | 美商博得學院股份有限公司 | Ｐｄｅ３調節劑反應性癌症之鑑定 |
| WO2020157188A1 (fr) * | 2019-02-01 | 2020-08-06 | Bayer Aktiengesellschaft | Dihydrooxadiazinones pour le traitement de maladies hyperprolifératives |
| TWI750573B (zh) | 2019-02-01 | 2021-12-21 | 德商拜耳廠股份有限公司 | 1,2,4-三-3(2h)-酮化合物 |
| CN117279644A (zh) | 2021-03-03 | 2023-12-22 | 拜耳股份有限公司 | 用于治疗肉瘤的取代的3,6-二氢-2h-1,3,4-噁二嗪-2-酮 |
| EP4289828A1 (fr) | 2022-06-10 | 2023-12-13 | Bayer Aktiengesellschaft | Procédé de préparation d'une 3,6-dihydro-2h-1,3,4-oxadiazine-2-one |
| EP4289829A1 (fr) | 2022-06-10 | 2023-12-13 | Bayer Aktiengesellschaft | Formes cristallines de (6s)-5-[4'-fluoro-2-(trifluorométhyl)]-6-methyl-3,6-dihydro- 2h-1,3,4-oxadiazine-2-one biphényl-4-yl |
| CN120187704A (zh) * | 2022-11-24 | 2025-06-20 | 盛睿泽华医药科技（苏州）有限公司 | 吡啶酮化合物及其制备方法和用途 |
| CN117903077B (zh) * | 2023-01-13 | 2024-09-03 | 上海超阳药业有限公司 | 二氢噁二嗪酮化合物及其应用 |
| CN118420559B (zh) * | 2023-04-27 | 2025-02-14 | 上海超阳药业有限公司 | 氘代噁二嗪酮化合物及其用途 |
| CN118047833B (zh) * | 2024-01-31 | 2025-03-14 | 海南大学 | 含二茂铁的取代氨基乙酰胺类化合物及其制备方法和应用 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4097671A (en) * | 1975-08-28 | 1978-06-27 | General Electric Company | Dihydrooxadiazinones and method for making |
| US4052395A (en) | 1975-09-11 | 1977-10-04 | Sankyo Company Limited | Agricultural fungicidal compositions containing 6-(substituted phenyl)-pyridazinones and said pyridazinones |
| US4258094A (en) * | 1979-04-26 | 1981-03-24 | Brunswick Corporation | Melt bonded fabrics and a method for their production |
| US4334030A (en) | 1979-11-23 | 1982-06-08 | General Electric Company | Thermoplastic foamable blends |
| EP0052442B1 (fr) | 1980-11-14 | 1985-09-11 | Imperial Chemical Industries Plc | Composés hétérocycliques |
| ATE13294T1 (de) | 1981-03-04 | 1985-06-15 | Ciba Geigy Ag | Pyridazinone, verfahren zu ihrer herstellung, pharmazeutische praeparate enthaltend diese verbindungen und deren verwendung. |
| US4495185A (en) | 1981-11-12 | 1985-01-22 | Imperial Chemical Industries, Plc | 1,2,4-Triazin-3(2H) ones |
| ZA827641B (en) | 1981-11-12 | 1983-09-28 | Ici Plc | Thiadiazine, oxadiazine and triazine derivatives which possess cardiotonic and/or antihypertensive activity |
| US4581356A (en) | 1983-03-22 | 1986-04-08 | Fujisawa Pharmaceutical Co., Ltd. | Triazine derivatives, and pharmaceutical compositions comprising the same |
| GB8310435D0 (en) | 1983-04-18 | 1983-05-25 | Fujisawa Pharmaceutical Co | Triazine derivatives |
| JPS59196874A (ja) | 1983-04-22 | 1984-11-08 | Fujisawa Pharmaceut Co Ltd | トリアジン誘導体 |
| JPS6153270A (ja) | 1984-08-17 | 1986-03-17 | チバ・ガイギー・アクチエンゲゼルシヤフト | 置換ピリダジノン、その製造方法及び該化合物を含む医薬製剤 |
| US4816454A (en) | 1984-09-21 | 1989-03-28 | Cassella Aktiengesellschaft | 4,5-dihydro-3(2H)-pyridazinones and their pharmacological use |
| GB8426804D0 (en) | 1984-10-23 | 1984-11-28 | Ciba Geigy Ag | Pyridazinones preparations |
| ES2031821T3 (es) | 1985-10-17 | 1993-01-01 | Smith Kline & French Laboratories Limited | Procedimiento para preparar derivados de 4(4-oxo-1,4-dihidropiridin-1-il)fenilo. |
| EP0303418A3 (fr) | 1987-08-11 | 1990-11-07 | Smithkline Beecham Laboratoires Pharmaceutiques | Indolones substituées utiles dans le traitement des maladies cardiaques ou asthmatiques |
| DE69131268T2 (de) | 1990-09-21 | 1999-12-30 | Rohm And Haas Co., Philadelphia | Dihydropyridazinone und Pyridazinone als Fungizide |
| JPH0676325B2 (ja) * | 1992-05-08 | 1994-09-28 | 三井東圧化学株式会社 | オキサジアジン誘導体を有効成分として含有する抗血栓剤 |
| HUT68424A (en) | 1992-07-01 | 1995-06-28 | Ortho Pharma Corp | Novel 1-arylsulphonyl-, -arylcarbonyl- and 1-arylphosphonyl-3-phenyl-1,4,5,6-tetrahydro-pyridazines |
| JPH07291968A (ja) | 1994-04-26 | 1995-11-07 | Mitsubishi Chem Corp | トリアジノン誘導体またはその塩類 |
| DE19929787A1 (de) * | 1999-06-29 | 2001-01-04 | Bayer Ag | Neue 4-(2-Oxodihydrooxadiazinylphenyl)amide und ihre Verwendung |
| US20050070529A1 (en) * | 2001-02-12 | 2005-03-31 | Merk Pantent Gmbh | Use of type 4 phosphodiesterase inhibitors in myocardial diseases |
| WO2008108602A1 (fr) | 2007-03-07 | 2008-09-12 | Dong-A Pharm. Co., Ltd. | Nouveaux dérivés d'acide phénylpropionique utilisés en tant que modulateurs du récepteur gamma activé de la prolifération des peroxisomes, procédé de préparation de ceux-ci et composition pharmaceutique les comprenant |
| US9212146B2 (en) | 2008-03-18 | 2015-12-15 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Substituted pyridazinones for the treatment of tumors |
| CN101537006B (zh) | 2008-03-18 | 2012-06-06 | 中国科学院上海药物研究所 | 哒嗪酮类化合物在制备抗肿瘤药物中的用途 |
| EP2419400A1 (fr) | 2009-04-15 | 2012-02-22 | Research Triangle Institute | Inhibiteurs de la recapture des monoamines |
| FR2948940B1 (fr) * | 2009-08-04 | 2011-07-22 | Servier Lab | Nouveaux derives dihydroindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| JP5794297B2 (ja) | 2010-05-07 | 2015-10-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｇｐｒ１１９アゴニストとしてのピリダジノン |
| US8791162B2 (en) | 2011-02-14 | 2014-07-29 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
| TWI532742B (zh) | 2011-02-28 | 2016-05-11 | 艾伯維有限公司 | 激酶之三環抑制劑 |
| WO2014164704A2 (fr) * | 2013-03-11 | 2014-10-09 | The Broad Institute, Inc. | Composés et compositions utilisables en vue du traitement du cancer |
| TWI656121B (zh) * | 2014-08-04 | 2019-04-11 | 德商拜耳製藥公司 | ２－（嗎啉－４－基）－１，７－萘啶 |
| EP3334404B1 (fr) * | 2015-08-13 | 2024-09-18 | The Broad Institute, Inc. | Compositions et procédés pour la détection de cellules cancéreuses exprimant pde3a et slfn12 |
| CA3011189C (fr) | 2016-01-14 | 2024-02-20 | Bayer Pharma Aktiengesellschaft | 2-(morpholin-4-yl)-1,7-naphthyridines substituees en 5 |
| US10966986B2 (en) | 2016-02-05 | 2021-04-06 | Bayer Pharma Aktiengesellschaft | Compounds, compositions and methods for cancer patient stratification and cancer treatment |
| KR101831772B1 (ko) * | 2016-03-24 | 2018-03-06 | 아이디에스(주) | 복합 광원 모듈을 가지는 카메라 접사용 기구 및 이를 이용한 지문 시편 촬영 방법 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| CA3071795A1 (fr) | 2017-08-04 | 2019-02-07 | Bayer Aktiengesellschaft | Derives de 6-phenyl-4,5-dihydropyridazin-3(2h)-one utilises en tant qu'inhibiteurs de pde3a et pde3b pour le traitement du cancer |
| JOP20200024A1 (ar) | 2017-08-04 | 2020-02-02 | Bayer Ag | مركبات ثنائي هيدروكساديازينون |
| TW202031677A (zh) | 2018-11-01 | 2020-09-01 | 美商博得學院股份有限公司 | Ｐｄｅ３調節劑反應性癌症之鑑定 |
| TWI750573B (zh) | 2019-02-01 | 2021-12-21 | 德商拜耳廠股份有限公司 | 1,2,4-三-3(2h)-酮化合物 |
-
2018
- 2018-08-01 JO JOP/2020/0024A patent/JOP20200024A1/ar unknown
- 2018-08-02 MA MA049750A patent/MA49750A/fr unknown
- 2018-08-02 CA CA3071800A patent/CA3071800A1/fr active Pending
- 2018-08-02 MX MX2020001404A patent/MX2020001404A/es unknown
- 2018-08-02 PE PE2020000184A patent/PE20200936A1/es unknown
- 2018-08-02 UA UAA202001558A patent/UA125731C2/uk unknown
- 2018-08-02 KR KR1020207005998A patent/KR20200036914A/ko not_active Withdrawn
- 2018-08-02 US US16/635,504 patent/US11427553B2/en active Active
- 2018-08-02 EP EP18755153.6A patent/EP3661517B1/fr active Active
- 2018-08-02 WO PCT/EP2018/071039 patent/WO2019025562A1/fr not_active Ceased
- 2018-08-02 CN CN201880050751.0A patent/CN111212647B/zh active Active
- 2018-08-02 AU AU2018309356A patent/AU2018309356B2/en not_active Ceased
- 2018-08-02 JP JP2020505898A patent/JP7676141B2/ja active Active
- 2018-08-02 CR CR20200057A patent/CR20200057A/es unknown
- 2018-08-02 SG SG11201913775UA patent/SG11201913775UA/en unknown
- 2018-08-02 BR BR112020002351-5A patent/BR112020002351A2/pt not_active IP Right Cessation
- 2018-08-02 CU CU2020000008A patent/CU24608B1/es unknown
- 2018-08-02 EA EA202090448A patent/EA202090448A1/ru unknown
- 2018-08-03 UY UY0001037832A patent/UY37832A/es not_active Application Discontinuation
- 2018-08-03 AR ARP180102218 patent/AR112402A1/es not_active Application Discontinuation
- 2018-08-03 TW TW107127172A patent/TWI791581B/zh not_active IP Right Cessation
-
2020
- 2020-01-16 IL IL272098A patent/IL272098B2/en unknown
- 2020-01-17 PH PH12020500134A patent/PH12020500134A1/en unknown
- 2020-02-04 EC ECSENADI20208441A patent/ECSP20008441A/es unknown
- 2020-02-04 CO CONC2020/0001242A patent/CO2020001242A2/es unknown
- 2020-02-04 CL CL2020000303A patent/CL2020000303A1/es unknown
-
2022
- 2022-07-11 US US17/862,255 patent/US12258323B2/en active Active
- 2022-07-14 US US17/865,236 patent/US11773070B2/en active Active
-
2023
- 2023-06-13 JP JP2023097166A patent/JP2023115065A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11773070B2 (en) | Dihydrooxadiazinones | |
| WO2018077944A2 (fr) | 1,2,4-triazolones 4,5-annelées | |
| EP3319945A1 (fr) | 2-aryl- et 2-arylalkyl-benzimidazoles utilisés comme inhibiteurs de midh1 | |
| US20240182452A1 (en) | 6-phenyl-4,5-dihydropyridazin-3(2h)-one derivatives as pde3a and pde3b inhibitors for treating cancer | |
| WO2018210729A1 (fr) | Dérivés de sulfonamide aromatiques utilisés en tant qu'antagonistes ou modulateurs allostériques négatifs du récepteur p2x4 | |
| US20250170136A1 (en) | 1,2,4-triazin-3(2h)-one compounds for the treatment of hyperproliferative diseases | |
| WO2020157201A1 (fr) | Composés d'oxadiazinone pour le traitement de maladies hyperprolifératives | |
| WO2017207534A1 (fr) | Composés hétéroarylbenzimidazole substitués | |
| WO2020157199A1 (fr) | Composés dihydropyridazinone annelés utilisés en tant que composés anticancéreux | |
| EA041614B1 (ru) | Дигидрооксадиазиноны | |
| WO2020157236A1 (fr) | Dihydrooxadiazinones à substitution pyridyle | |
| HK40025099B (zh) | 二氢恶二嗪酮 | |
| WO2020048831A1 (fr) | Composés 5-aryl-3,9-diazaspiro[5.5]undécan-2-one | |
| WO2020157189A1 (fr) | Composés de 1,2,4-triazin-6(1h)-one pour le traitement de maladies hyperprolifératives | |
| HK40025099A (en) | Dihydrooxadiazinones |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R13-asn-PN2301 St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PC1202 | Submission of document of withdrawal before decision of registration |
St.27 status event code: N-1-6-B10-B11-nap-PC1202 |